{"id":4257,"date":"2025-04-29T13:50:44","date_gmt":"2025-04-29T13:50:44","guid":{"rendered":"https:\/\/gunnewsusa.com\/index.php\/2025\/04\/29\/astrazeneca-moves-some-production-to-us-amid-tariff-threat\/"},"modified":"2025-04-29T13:50:46","modified_gmt":"2025-04-29T13:50:46","slug":"astrazeneca-moves-some-production-to-us-amid-tariff-threat","status":"publish","type":"post","link":"https:\/\/gunnewsusa.com\/index.php\/2025\/04\/29\/astrazeneca-moves-some-production-to-us-amid-tariff-threat\/","title":{"rendered":"AstraZeneca Moves Some Production To US Amid Tariff Threat"},"content":{"rendered":"<p><\/p>\n<div id=\"ignorediv\">\n                                        <!-- Story Text --><br \/>\n                                                                                                                        <b class=\"place_cont\">London: <\/b><\/p>\n<p>British pharmaceutical giant AstraZeneca announced Tuesday that it has begun moving some of its European production to the United States, ahead of President Donald Trump&#8217;s possible tariffs on the sector.<\/p>\n<p>&#8220;Our company is firmly committed to investing and growing in the US,&#8221; chief executive Pascal Soriot said in an earnings statement, which also reported that first-quarter profit rose by over 30 percent to $2.92 billion.<\/p>\n<p>The United States earlier in April opened the door to potential tariffs targeting pharmaceuticals, which have so far benefited from exemptions to Trump&#8217;s sweeping levies on imports from trading partners.<\/p>\n<p><!--MIDTABOOLA--><\/p>\n<p>Trump has also imposed a series of sector-specific levies, slapping tariffs on imports of steel, aluminium and autos, before launching a &#8220;national security&#8221; investigation into pharmaceutical imports.<\/p>\n<p>AstraZeneca could become exposed to US levies on its European-made products but Soriot stressed that the impact would be limited due to the ongoing shift in production.<\/p>\n<p>&#8220;The limit of the exposure we have relates to exporting products from Europe to the US,&#8221; Soriot said on an earnings call.<\/p>\n<p>&#8220;We are in the process of shifting the manufacturing of those products to the US,&#8221; he added.<\/p>\n<p>The United States is a key market for the pharmaceutical industry, and AstraZeneca was already planning to invest $3.5 billion there by the end of 2026.<\/p>\n<p>Soriot said earlier in the year that he hoped the US will account for around half of AstraZeneca&#8217;s global revenue by 2030.<\/p>\n<p><!--#VuukleAD--><\/p>\n<p>Other pharmaceutical companies have also announced plans to increase investments in the United States.<\/p>\n<p>AstraZeneca reconfirmed its outlook on Tuesday, saying it remains on track to achieve its target of $80 billion in annual revenue by the end of the decade.<\/p>\n<p>Its first-quarter profit in 2025 benefited from strong growth in its cancer drug sales and biopharmaceuticals.<\/p>\n<p>During the quarter, it generated 42 percent of its revenue in the United States, followed by 20 percent in Europe.<\/p>\n<p><i>(This story has not been edited by NDTV staff and is auto-generated from a syndicated feed.)<\/i><\/p>\n<p>                                                                                <!-- Featured Video --><br \/>\n                                                                                                                        <!-- Recommended Widget -->\n                                                                                                                    <\/div>\n","protected":false},"excerpt":{"rendered":"<p>London: British pharmaceutical giant AstraZeneca announced Tuesday that it has begun moving some of its European production to the United States, ahead of President Donald Trump&#8217;s possible tariffs on the sector. &#8220;Our company is firmly committed to investing and growing in the US,&#8221; chief executive Pascal Soriot said in an earnings statement, which also reported [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4258,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"tdm_status":"","tdm_grid_status":"","footnotes":""},"categories":[19],"tags":[],"class_list":{"0":"post-4257","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-world-news"},"_links":{"self":[{"href":"https:\/\/gunnewsusa.com\/index.php\/wp-json\/wp\/v2\/posts\/4257","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/gunnewsusa.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/gunnewsusa.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/gunnewsusa.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/gunnewsusa.com\/index.php\/wp-json\/wp\/v2\/comments?post=4257"}],"version-history":[{"count":1,"href":"https:\/\/gunnewsusa.com\/index.php\/wp-json\/wp\/v2\/posts\/4257\/revisions"}],"predecessor-version":[{"id":4259,"href":"https:\/\/gunnewsusa.com\/index.php\/wp-json\/wp\/v2\/posts\/4257\/revisions\/4259"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/gunnewsusa.com\/index.php\/wp-json\/wp\/v2\/media\/4258"}],"wp:attachment":[{"href":"https:\/\/gunnewsusa.com\/index.php\/wp-json\/wp\/v2\/media?parent=4257"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/gunnewsusa.com\/index.php\/wp-json\/wp\/v2\/categories?post=4257"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/gunnewsusa.com\/index.php\/wp-json\/wp\/v2\/tags?post=4257"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}